Hep C field is already too crowded.
Biota's Vapendavir, RSV and the anti-bacteria program should be the catalysts for big pharmaceuticals to look at.
- Forums
- ASX - By Stock
- BTA
- Ann: Relenza March Quarter Royalty
Ann: Relenza March Quarter Royalty , page-18
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)